Cannabis Law Report

JUNE 7, 2021

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

DECEMBER 17, 2021

Deletion Syndrome – Global Market Insights, Epidemiology and Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. deletion syndrome in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030. Country-Wise Epidemiology.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Therapy 52

Cannabis Law Report

FEBRUARY 3, 2022

DUBLIN–(BUSINESS WIRE)–The “Global Cannabis Market- Market Size & Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. million by 2030 at a CAGR of 23.9%, 2021-2030. Clinical Trials of Cannabis Are Still on Going. German Narcotics Act. Narcotics Act (No.8)

Indica 52

Indica Oil Legalization Clinical Trials 52

Cannabis Law Report

JUNE 30, 2021

According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated.

Treatment 52

Treatment Clinical Trials Research and Development Data 52